DEPO-MEDROL (methylprednisolone acetate)
DEPO-MEDROL is indicated for the treatment of Asthma; Atopic Dermatitis; Contact Dermatitis; Drug Hypersensitivity; Serum Sickness; Transfusion Reaction; Bullous Dermatitis Herpetiformis; Exfoliative Erythroderma; Mycosis Fungoides; Pemphigus.
Development Insights
Details
- Status
- Prescription
- First Approved
- 1959-05-27
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
DEPO-MEDROL Approval History
What DEPO-MEDROL Treats
10 indicationsDEPO-MEDROL is approved for 10 conditions since its original approval in 1959. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Asthma
- Atopic Dermatitis
- Contact Dermatitis
- Drug Hypersensitivity
- Serum Sickness
- Transfusion Reaction
- Bullous Dermatitis Herpetiformis
- Exfoliative Erythroderma
DEPO-MEDROL Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in DEPO-MEDROL's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications DEPO-MEDROL treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to DEPO-MEDROL
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
6 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05929755 | 23-090-2 | Ph 4 | recruiting | Depo-Medrol on Psoas After LLIF |
| NCT03913702 results posted | UTMB IRB #: 18-0156 | Ph 2 | terminated | Subacromial Methylprednisolone Versus Ketorolac for Shoulder Impingement |
| NCT03794505 | F-2018-3401-056 | Ph 3 | completed | Quality of Life and Pain With Infiltration or Suprascapular Nerve Block in Glenohumeral Arthirtis |
| NCT02847494 results posted | 2016-6342 | Ph 4 | completed | Corticosteroids for Acute Migraine in the Emergency Department |
| NCT02403856 CALCECHO | RC15_0019 | Ph 4 | completed | Efficacy and Tolerance of Ultrasound-guided Needling and Lavage of Calcific Tendinitis of the Rotator Cuff Performed With or Without Subacromial Corticosteroid Injection |
| NCT01652495 TPESP2011-12 results posted | 2012-000866-40 | Ph 4 | completed | Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
DEPO-MEDROL FDA Label Details
Indications & Usage
FDA Label (PDF)DEPO-MEDROL is indicated for the treatment of Asthma; Atopic Dermatitis; Contact Dermatitis; Drug Hypersensitivity; Serum Sickness; Transfusion Reaction; Bullous Dermatitis Herpetiformis; Exfoliative Erythroderma; Mycosis Fungoides; Pemphigus.
Explore on TheraRadar
Ulcerative Colitis Drug Landscape 2026
Approved therapies, pipeline drugs, and clinical trial intelligence
Related Intelligence
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment